Structure Therapeutics Inc.

Structure Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for chronic diseases with unmet medical needs. The company focuses on G-protein coupled receptor (GPCR) modulation as its core scientific platform. Its lead candidate, GSBR-1290, is a glucagon-like-peptide-1 receptor agonist currently in two phase 2 clinical trials for obesity and related weight management indications. The company also advances ANPA-0073, targeting the apelin receptor and positioned as phase 2-ready for weight loss applications, and LTSE-2578, a lysophosphatidic acid 1 receptor antagonist in development for idiopathic pulmonary fibrosis.

Beyond its lead programs, Structure Therapeutics maintains a pipeline of earlier-stage candidates including ACCG-2671 for obesity and preclinical programs targeting GIPR and GCG receptors, with dual agonist combinations being explored for metabolic indications. These programs represent the company's strategy to address obesity through multiple mechanistic approaches.

Headquartered in South San Francisco, California, Structure Therapeutics operates with approximately 218 full-time employees. The company was incorporated in 2016 and is incorporated in the Cayman Islands, with its primary operations and market focus in the United States. As a clinical-stage enterprise, the company has not yet generated product revenues.